Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.09. | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 803 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
OREXO Aktie jetzt für 0€ handeln | |||||
05.09. | Orexo AB: Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 97 | GlobeNewswire (Europe) | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared... ► Artikel lesen | |
29.08. | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 301 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
16.07. | Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds | 1 | Investing.com | ||
16.07. | Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest | 1 | Investing.com Deutsch | ||
16.07. | Orexo AB: Orexo Q2 2025 Interim Report | 154 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
02.06. | Orexo to present clinical data for OX640 at the EAACI Congress | 257 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
06.05. | Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements | 1 | Investing.com | ||
06.05. | Orexo AB: Orexo Q1 2025 Interim Report | 199 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
10.04. | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 392 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 177 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 476 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 507 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 404 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 369 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
24.10.24 | Orexo Interim Report Q3 2024 | 516 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
04.10.24 | Orexo's Nomination Committee for the Annual General Meeting 2025 | 386 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 4,195 | -0,59 % | BRISANTE Meldung setzt Aurora Cannabis Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
ABBVIE | 186,60 | +2,30 % | AbbVie Aktienanalyse - Top Pharmaaktie zum fairen Preis? | Pharmaaktien sind in geringerem Ausmaß von konjunkturellen Risiken abhängig. Schließlich werden Medikamente jederzeit verabreicht und benötigt. Deshalb gelten Pharmaaktien als stabile Werte und sind... ► Artikel lesen | |
TILRAY BRANDS | 1,025 | -0,73 % | Tilray Brands, Inc.: Broken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain "Sprits 26", Elevates Craft Portfolio with Modern Blue Dream Release | ||
BRISTOL-MYERS SQUIBB | 39,140 | +0,20 % | Bristol-Myers Squibb declares $0.62 dividend | ||
TEVA | 15,600 | -0,64 % | Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation | Regulatory News:
Medincell (Paris:MEDCL):
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,... ► Artikel lesen | |
BAUSCH HEALTH | 5,841 | +2,38 % | Bausch Health Companies Inc.: Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio | The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL... ► Artikel lesen | |
BIONANO GENOMICS | 1,770 | 0,00 % | Crude Oil Rises Over 2%; Bionano Genomics Shares Plunge | ||
OPKO HEALTH | 1,171 | +0,29 % | OPKO HEALTH, INC. - 8-K, Current Report | ||
JAGUAR HEALTH | 1,860 | -5,58 % | Jaguar Health, Inc. - 8-K, Current Report | ||
MALLINCKRODT | - | - | Mallinckrodt plc: Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer | DUBLIN, Aug. 6, 2025 /PRNewswire/ -- Mallinckrodt plc today announced the appointment of Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.... ► Artikel lesen | |
AVALO THERAPEUTICS | 9,620 | +17,03 % | Avalo Therapeutics: Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates | Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately... ► Artikel lesen | |
BAYER | 27,380 | +1,63 % | Onkologie-Boom: So könnten Bayer, Vidac Pharma und BioNTech mit ihren vollen Pipelines outperformen | Die Onkologie-Branche steht vor einer beispiellosen Wachstumswelle: Der globale Markt soll sich bis 2034 auf über 866 Mrd. USD verdoppeln. Getrieben durch demografische Faktoren, bahnbrechende Immuntherapien... ► Artikel lesen | |
MERCK KGAA | 107,65 | +1,13 % | BERNSTEIN RESEARCH stuft MERCK KGAA auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Merck KGaA nach einer Investorenveranstaltung auf "Market-Perform" mit einem Kursziel von 138 Euro belassen.... ► Artikel lesen | |
NOVO NORDISK | 49,285 | +2,20 % | Pharma-Schock: Umstrukturierung im Kampf gegen Eli Lilly - Novo Nordisk streicht 9000 Stellen | © Foto: Christian Schultz/dpaNovo Nordisk startet einen radikalen Umbau mit massiven Stellenstreichungen, um trotz wachsendem Druck im Adipositasmarkt seine Spitzenposition zu sichern.Der dänische Pharmariese... ► Artikel lesen | |
ELI LILLY | 652,10 | +1,30 % | Lilly's Mounjaro shows strong results in pediatric diabetes trial |